Literature DB >> 16757587

Candidemia in Norway (1991 to 2003): results from a nationwide study.

Per Sandven1, Lars Bevanger, Asbjørn Digranes, Hanne H Haukland, Turid Mannsåker, Peter Gaustad.   

Abstract

A long-term, nationwide prospective candidemia study has been ongoing in Norway since 1991. All medical microbiological laboratories in the country have participated. During the period 1991 to 2003 a total of 1,393 episodes of candidemia occurred in 1,348 patients. The incidence of candidemia episodes per 100,000 inhabitants increased from approximately 2 episodes in the early 1990s to 3 episodes in 2001 to 2003. The average annual incidences varied markedly between the age groups. The incidence was high in patients aged < 1 year and in patients aged > or = 70 years. In patients > or = 80 years of age, the incidence has increased during the last 3 years from an annual average of 6.5 to 15.6 cases/100,000 inhabitants in 2003. Four Candida species (C. albicans [70%], C. glabrata [13%], C. tropicalis [7%], and C. parapsilosis [6%]) accounted for 95.5% of the isolates. The species distribution has been constant during the 13-year study period. The distribution of the most important species varied with the age of the patient. In patients < 1 year of age, the majority of episodes were caused by C. albicans (91%). The occurrence of C. glabrata increased with age. In patients > or = 80 years of age, approximately 1/3 of all episodes were due to this species. All C. albicans strains were susceptible to fluconazole. The percentage of yeast isolates with decreased susceptibility to fluconazole (MICs > or = 16 microg/ml) was 10.7% during the first period of this study (1991 to 1996) and 11.7% during the second period (1997 to 2003).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757587      PMCID: PMC1489391          DOI: 10.1128/JCM.00029-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management.

Authors:  C J Clancy; F Barchiesi; L Falconi DiFrancesco; A J Morris; D R Snydman; V L Yu; G Scalise; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-08       Impact factor: 3.267

Review 2.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

Authors:  Philippe Eggimann; Jorge Garbino; Didier Pittet
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

3.  Epidemiology of candidemia.

Authors:  P Sandven
Journal:  Rev Iberoam Micol       Date:  2000-09       Impact factor: 1.044

4.  Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.

Authors:  Maiken Cavling Arendrup; Kurt Fuursted; Bente Gahrn-Hansen; Irene Møller Jensen; Jenny Dahl Knudsen; Bettina Lundgren; Henrik C Schønheyder; Michael Tvede
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

6.  Candida glabrata fungemia: experience in a tertiary care center.

Authors:  Anurag Malani; Jareer Hmoud; Loretta Chiu; Peggy L Carver; Andrew Bielaczyc; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2005-08-24       Impact factor: 9.079

7.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

8.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Authors:  Lena Rós Asmundsdóttir; Helga Erlendsdóttir; Magnús Gottfredsson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection.

Authors:  Lynn L Horvath; Benjamin J George; Clinton K Murray; Linda S Harrison; Duane R Hospenthal
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more
  49 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia.

Authors:  F Lamoth; K Jaton; G Prod'hom; L Senn; J Bille; T Calandra; O Marchetti
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Neonatal candidiasis: epidemiology, risk factors, and clinical judgment.

Authors:  Daniel K Benjamin; Barbara J Stoll; Marie G Gantz; Michele C Walsh; Pablo J Sánchez; Abhik Das; Seetha Shankaran; Rosemary D Higgins; Kathy J Auten; Nancy A Miller; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Rachel L Chapman; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg
Journal:  Pediatrics       Date:  2010-09-27       Impact factor: 7.124

5.  Does one voriconazole breakpoint suit all Candida species?

Authors:  Maiken Cavling Arendrup; David W Denning; M A Pfaller; D J Diekema; J H Rex
Journal:  J Clin Microbiol       Date:  2007-06       Impact factor: 5.948

Review 6.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

8.  In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Authors:  He Wang; Meng Xiao; Sharon C-A Chen; Fanrong Kong; Zi-Yong Sun; Kang Liao; Juan Lu; Hai-Feng Shao; Yan Yan; Hong Fan; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

9.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

Authors:  Guy St-Germain; Michel Laverdière; René Pelletier; Pierre René; Anne-Marie Bourgault; Claude Lemieux; Michael Libman
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

10.  Candida glabrata environmental stress response involves Saccharomyces cerevisiae Msn2/4 orthologous transcription factors.

Authors:  Andreas Roetzer; Christa Gregori; Ann Marie Jennings; Jessica Quintin; Dominique Ferrandon; Geraldine Butler; Karl Kuchler; Gustav Ammerer; Christoph Schüller
Journal:  Mol Microbiol       Date:  2008-06-28       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.